Matt Might
Matthew Might, PhD
Senior Lecturer on Biomedical Informatics, Part-time, Harvard Medical School

Matt Might  has been the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) since 2017. At UAB, he is the Hugh Kaul Kaul Endowed Chair of Personalized Medicine, a Professor of Internal Medicine and a Professor of Computer Science. His research at UAB focuses on precision prevention, diagnosis and therapeutics across rare disease, cancer and common/chronic conditions. A principal theme in his research is the use of computer and data science to enhance clinical and academic medicine.

From 2016 to 2018, Might was a Strategist in the Executive Office of the President in The White House. At The White House, he worked primarily on President Obama's Precision Medicine Initiative with both the NIH and the Department of Veterans Affairs.

In 2015, Might joined the faculty of the Department of Biomedical Informatics at Harvard Medical School. At DBMI, his research focuses on rare disease discovery and diagnosis, and on the development of personalized therapeutics for rare disease.

Might is co-founder and Chief Scientific Officer of, a non-profit dedicated to finding treatments for NGLY1 deficiency, and he was a co-founder and Scientific Advisor to Pairnomix, a start-up which identifies potential patient-specific therapies for rare disorders. Q State Biosciences acquired Pairnomix in October 2018, and Might remains a Scientific Advisor.

Cardioinformatics: the nexus of bioinformatics and precision cardiology.
Authors: Khomtchouk BB, Tran DT, Vand KA, Might M, Gozani O, Assimes TL.
Brief Bioinform
View full abstract on Pubmed
N-of-1 Precision Medicine and Research Oversight.
Authors: Crouse A, Nakano-Okuno M, Might M, May T.
Am J Bioeth
View full abstract on Pubmed
An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene.
Authors: Yang S, Cheng YS, Li R, Pradhan M, Hong J, Beers J, Zou J, Liu C, Might M, Rodems S, Zheng W.
Stem Cell Res
View full abstract on Pubmed
Induced pluripotent stem cells for neural drug discovery.
Authors: Farkhondeh A, Li R, Gorshkov K, Chen KG, Might M, Rodems S, Lo DC, Zheng W.
Drug Discov Today
View full abstract on Pubmed
Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene.
Authors: Li R, Pradhan M, Xu M, Baskfield A, Farkhondeh A, Cheng YS, Beers J, Zou J, Liu C, Might M, Rodems S, Zheng W.
Stem Cell Res
View full abstract on Pubmed
anexVis: visual analytics framework for analysis of RNA expression.
Authors: Tran DT, Zhang T, Stutsman R, Might M, Desai UR, Kuberan B.
View full abstract on Pubmed
Plain-language medical vocabulary for precision diagnosis.
Authors: Vasilevsky NA, Foster ED, Engelstad ME, Carmody L, Might M, Chambers C, Dawkins HJS, Lewis J, Della Rocca MG, Snyder M, Boerkoel CF, Rath A, Terry SF, Kent A, Searle B, Baynam G, Jones E, Gavin P, Bamshad M, Chong J, Groza T, Adams D, Resnick AC, Heath AP, Mungall C, Holm IA, Rageth K, Brownstein CA, Shefchek K, McMurry JA, Robinson PN, Köhler S, Haendel MA.
Nat Genet
View full abstract on Pubmed
A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.
Authors: Atkin TA, Maher CM, Gerlach AC, Gay BC, Antonio BM, Santos SC, Padilla KM, Rader J, Krafte DS, Fox MA, Stewart GR, Petrovski S, Devinsky O, Might M, Petrou S, Goldstein DB.
View full abstract on Pubmed
Transcriptome and functional analysis in a Drosophila model of NGLY1 deficiency provides insight into therapeutic approaches.
Authors: Owings KG, Lowry JB, Bi Y, Might M, Chow CY.
Hum Mol Genet
View full abstract on Pubmed
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-ß-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Authors: Bi Y, Might M, Vankayalapati H, Kuberan B.
Bioorg Med Chem Lett
View full abstract on Pubmed